EX1 Key Highlights • Exopharm was assigned the LEAP Technology from Altnia Operations, replacing the existing licensing agreement. • Exopharm converted to a public company as part of preparations for an Initial Public Offering and seed capital raising. • Exopharm raised $7m through a fully subscribed IPO and listed on the ASX in December. • Exopharm aims to be a leader in the field of human therapeutics using exosomes as regenerative medicine productsto treat health span related conditions. • Funding from the IPO is being used to fund a Development Program and accordingly the development andcommercialisation of the LEAP Technology and Plexaris and Exomere products. • The Company has sponsored testing of experimental Plexaris and Exomere product in an animal model of woundhealing by a contract research organisation (CRO) with results prepared and received following the end of the halfyear (refer to Non-Clinical Study Developments update in the following page).
EX1 Price at posting:
49.0¢ Sentiment: Buy Disclosure: Not Held
